Products Detials
RAXIME
Born to fight tough challenges
Ace amongst antibacterial
- Higher penetration in tissue
- Assured better clinical results
- Short-course therapy of tonsillopharyngitis
- Stable to b-lactamase hydrolysis
Cefuroxime INJECTION
Also available in : Cefuroxime 125mg./5ml. DRY SYRUP.
Dosage and Administration
Cefuroxime Sodium for Injection is for intravenous and/or intramuscular administration.
General Recommendations Adults
Many infections respond to 750mg three times daily by im or iv injection. For more severe infections the dose should be increased to 1.5g three times daily iv. The frequency of administration may be increased to 6-hourly if necessary, giving total daily doses of 3 to 6g.
Infants and Children
30 - 100mg/kg/day given as 3 or 4 divided doses. A dose of 60mg/kg/day is appropriate for most infections.
Neonates
30 - 100mg/kg/day given as 2 or 3 divided doses (see Pharmacokinetics section).
Gonorrhoea
1.5g as a single dose (as 2 x 750mg injections intramuscularly with different sites, e.g. each buttock).
- Respiratory tract infections
- Uncomplicated SSTI
- Meningitis
- Gonorrhoea
- Surgical prophylaxis
- Acute gonococcal urethritis
RAXIME is a second-generation cephalosporin antibiotic that has been widely available worldwide since 1977
As for the other cephalosporins, although as a second-generation it is less susceptible to Beta-lactamase and so may have greater activity against Haemophilus influenzae, Neisseria gonorrhoeae and Lyme disease. Unlike other second generation cephalosporins RAXIME can cross the blood-brain-barrier.
References
- Pichichero ME (2006). Cephalosporins can be prescribed safely for penicillin-allergic patients" (PDF). The Journal of family practice 55 (2)
Cefuroxime is a well characterised and effective antibacterial agent which has bactericidal activity against a wide range of common pathogens, including β-lactamase producing strains.
Cefuroxime has good stability to bacterial β-lactamase, and consequently is active against many ampicillin-resistant or amoxycillin-resistant strains.
The bactericidal action of cefuroxime results from inhibition of cell wall synthesis by binding to essential target proteins.
Cefuroxime is usually active against the following organisms in vitro.
